From the Division of Anesthesiology, Department of Anesthesiology, Clinical Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.
Division of Anesthesiology, Department of Anesthesiology, Intensive Care and Emergency Medicine, Ospedale Regionale di Lugano, Lugano, Switzerland.
Anesth Analg. 2021 Dec 1;133(6):1540-1549. doi: 10.1213/ANE.0000000000005324.
Succinylcholine remains the muscle relaxant of choice for rapid sequence induction (RSI) but has many adverse effects. High-dose rocuronium bromide may be an alternative to succinylcholine for RSI but recovery times are nearly doubled compared with a standard intubating dose of rocuronium. Magnesium sulfate significantly shortens the onset time of a standard intubating dose of rocuronium. We set out to investigate whether intravenous (IV) pretreatment with MgSO4 followed by a standard intubating dose of rocuronium achieved superior intubation conditions compared with succinylcholine.
Adults were randomized to receive a 15-minute IV infusion of MgSO4 (60 mg·kg-1) immediately before RSI with propofol 2 mg·kg-1, sufentanil 0.2 μg·kg-1 and rocuronium 0.6 mg·kg-1, or a matching 15-minute IV infusion of saline immediately before an identical RSI, but with succinylcholine 1 mg·kg-1. Primary end point was the rate of excellent intubating conditions 60 seconds after administration of the neuromuscular blocking agent and compared between groups using multivariable log-binomial regression model. Secondary end points were blood pressure and heart rate before induction, before and after intubation, and adverse events up to 24 hours postoperatively.
Among 280 randomized patients, intubating conditions could be analyzed in 259 (133 MgSO4-rocuronium and 126 saline-succinylcholine). The rate of excellent intubating conditions was 46% with MgSO4-rocuronium and 45% with saline-succinylcholine. The analysis adjusted for gender and center showed no superiority of MgSO4-rocuronium compared with saline-succinylcholine (relative risk [RR] 1.06, 95% confidence interval [CI], 0.81-1.39, P = .659). The rate of excellent intubating conditions was higher in women (54% [70 of 130]) compared with men (37% [48 of 129]; adjusted RR 1.42, 95% CI, 1.07-1.91, P = .017). No significant difference between groups was observed for systolic and diastolic blood pressures. Mean heart rate was significantly higher in the MgSO4-rocuronium group. The percentage of patients with at least 1 adverse event was lower with MgSO4-rocuronium (11%) compared with saline-succinylcholine (28%) (RR 0.38, 95% CI, 0.22-0.66, P < .001). With saline-succinylcholine, adverse events consisted mainly of postoperative muscle pain (n = 26 [19%]) and signs of histamine release (n = 13 [9%]). With MgSO4-rocuronium, few patients had pain on injection, nausea and vomiting, or skin rash during the MgSO4-infusion (n = 5 [4%]).
IV pretreatment with MgSO4 followed by a standard intubating dose of rocuronium did not provide superior intubation conditions to succinylcholine but had fewer adverse effects.
琥珀酰胆碱仍然是快速序贯诱导(RSI)的首选肌肉松弛剂,但有许多不良反应。高剂量罗库溴铵可能是琥珀酰胆碱用于 RSI 的替代药物,但与标准插管剂量的罗库溴铵相比,恢复时间几乎翻了一番。硫酸镁可显著缩短标准插管剂量罗库溴铵的起效时间。我们着手研究静脉(IV)预注硫酸镁后再给予标准插管剂量罗库溴铵是否能达到优于琥珀酰胆碱的插管条件。
成年人被随机分配在接受丙泊酚 2mg·kg-1、舒芬太尼 0.2μg·kg-1 和罗库溴铵 0.6mg·kg-1 的 RSI 前,接受 15 分钟 IV 输注硫酸镁(60mg·kg-1),或在接受相同的 RSI 前,接受 15 分钟 IV 输注生理盐水,但接受琥珀酰胆碱 1mg·kg-1。主要终点是在给予神经肌肉阻滞剂后 60 秒时的优秀插管条件的发生率,并使用多变量二项式回归模型比较组间差异。次要终点是诱导前、插管前和插管后的血压和心率,以及术后 24 小时内的不良反应。
在 280 名随机患者中,259 名(133 名硫酸镁-罗库溴铵和 126 名生理盐水-琥珀酰胆碱)可进行插管条件分析。硫酸镁-罗库溴铵组的优秀插管条件发生率为 46%,生理盐水-琥珀酰胆碱组为 45%。调整性别和中心因素后,硫酸镁-罗库溴铵与生理盐水-琥珀酰胆碱相比无优势(相对风险 [RR] 1.06,95%置信区间 [CI],0.81-1.39,P=0.659)。女性(54%[70/130])的优秀插管条件发生率高于男性(37%[48/129];调整 RR 1.42,95% CI,1.07-1.91,P=0.017)。两组间收缩压和舒张压无显著差异。硫酸镁-罗库溴铵组的平均心率显著升高。硫酸镁-罗库溴铵组至少发生 1 种不良反应的患者比例(11%)低于生理盐水-琥珀酰胆碱组(28%)(RR 0.38,95% CI,0.22-0.66,P<0.001)。生理盐水-琥珀酰胆碱组的不良反应主要为术后肌肉疼痛(n=26[19%])和组胺释放迹象(n=13[9%])。硫酸镁-罗库溴铵组中,少数患者在硫酸镁输注期间出现注射部位疼痛、恶心和呕吐或皮疹(n=5[4%])。
静脉预注硫酸镁后再给予标准插管剂量的罗库溴铵并不能提供优于琥珀酰胆碱的插管条件,但不良反应较少。